11/12
08:00 am
vor
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Medium
Report
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
11/8
10:05 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
11/8
08:46 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
High
Report
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
11/7
04:05 pm
vor
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
High
Report
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
10/1
07:13 am
vor
C-suite leaders race to keep up with the rapid pace of AI before competitors take the lead [Fortune]
High
Report
C-suite leaders race to keep up with the rapid pace of AI before competitors take the lead [Fortune]
9/30
07:00 am
vor
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Low
Report
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
9/6
11:04 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
9/6
08:08 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
9/5
04:01 pm
vor
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
High
Report
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
9/5
07:34 am
vor
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely [Yahoo! Finance]
Low
Report
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely [Yahoo! Finance]
8/28
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Medium
Report
Vor Bio to Participate in Upcoming Investor Conferences